Christopher Yasiejko
Correspondents at Bloomberg News
Patents/®️/©️, IP@BLaw. Past: @business, @nytimes, @delawareonline. Bylines: @PhillyInquirer, @PhillyDailyNews, @CJR, +. Views=mine. RT≠endorsement. Tips? DM.
Articles
-
4 days ago |
news.bloombergtax.com | Christopher Yasiejko |Michael Shapiro
The US Supreme Court declined to hear a case that asked whether patent holders can collect royalties after their patents expire, rejecting Atrium Medical Corp.'s request in a licensing fight with CR Bard Inc. The justices on Monday rejected Atrium’s petition for a writ of certiorari, allowing the US Court of Appeals for the Ninth Circuit’s August 2024 ruling to stand.
-
1 week ago |
news.bloomberglaw.com | Christopher Yasiejko
COURT: D. Del. TRACK DOCKET: No. 25-cv-659 (Bloomberg Law subscription)Fujirebio Diagnostics Inc., developer of the first FDA-approved blood test for Alzheimer’s disease, filed a lawsuit seeking a federal court’s ruling that its test doesn’t violate a Quanterix Corp. patent, aiming to clear the way for a US launch planned for late June.
-
1 week ago |
news.bloomberglaw.com | Christopher Yasiejko
May 30, 2025, 6:48 PM UTC Christopher Yasiejko Senior correspondent The US Supreme Court is seen on the first day of a new term in Washington, DC, Oct. 7, 2019. Photo by SAUL LOEB/AFP via Getty Images Drugmakers face new risks for device-related patentsTeva warns of sweeping impact if ruling is left standingChief Justice John Roberts gave Teva Pharmaceutical Industries Ltd.
-
1 week ago |
news.bloombergtax.com | Christopher Yasiejko
Chief Justice John Roberts gave Teva Pharmaceutical Industries Ltd. until July 31 to file a petition challenging an appeals court ruling it argued puts hundreds of patents at risk under a new interpretation of federal drug laws. Roberts in a Thursday order granted Teva’s May 22 request for more time, which it said was necessary for its petition challenging the US Court of Appeals for the Federal Circuit’s Dec. 20 decision.
-
1 week ago |
news.bloomberglaw.com | Christopher Yasiejko
and OptiMorphix Inc. settled a federal lawsuit over patents for mobile video and web-optimization technologies, according to a court order. Judge Maryellen Noreika on Wednesday approved a joint motion to dismiss that doesn’t allow OptiMorphix to renew its allegations but leaves the door open for Meta to renew its claims, defenses, or counterclaims, according to an order issued in the US District Court for the District of Delaware. • OptiMorphix sued Meta on Dec.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 688
- Tweets
- 2K
- DMs Open
- Yes
Import 300K bottles of generic Entresto in August & 2,200 kg of the blockbuster heart-failure drug’s active ingredient in December, and what do you get? A @Novartis suit seeking damages for @MSNLabs' alleged infringement of a recently revived patent. https://t.co/EaQPvBdVPw
Thanks for the shout-out, @cmorten2! And thanks to Chris Morten (of @ColumbiaLaw), @PrEP4AllNow, @TAGTeam_Tweets & @reshmagar, each of whom shared time and energy discussing the basis for their perspectives on @HHSGov's settlement last week w/ @GileadSciences on PrEP drugs.
@yasiejko (@bloomberglaw) has a new follow-up story on the landmark settlement in US v. Gilead—the billion-dollar patent fight over HIV PrEP. I'm quoted, along with Jeremiah Johnson (@PrEP4AllNow), Mark Harrington (@TAGTeam_Tweets) and @reshmagar. 1/ https://t.co/OH2KZjPohR
From the SIGN HERE; NO, REALLY Dept.🖋️: @AstellasUS can’t enforce a patent-infringement settlement with @MSNLabs over a generic version of the overactive-bladder drug Myrbetriq because the deal was never signed, a federal judge ruled. https://t.co/EQ6L9PvNg0